Cite
Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
MLA
Askanase, Anca D., et al. “Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.” Rheumatology & Therapy, vol. 8, no. 4, Dec. 2021, pp. 1871–86. EBSCOhost, https://doi.org/10.1007/s40744-021-00351-7.
APA
Askanase, A. D., Wright, D., Zhao, E., Zhu, J., Bilyk, R., & Furie, R. A. (2021). Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus. Rheumatology & Therapy, 8(4), 1871–1886. https://doi.org/10.1007/s40744-021-00351-7
Chicago
Askanase, Anca D., Dale Wright, Enxu Zhao, Julie Zhu, Roman Bilyk, and Richard A. Furie. 2021. “Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.” Rheumatology & Therapy 8 (4): 1871–86. doi:10.1007/s40744-021-00351-7.